Tempus AI Inc. (NASDAQ:TEM) shares are up during Wednesday’s session as the company announced promising results from the ALERT trial, which evaluates an automated electronic health record (EHR) notification system.

ALERT Trial Shows Improved Intervention Rates

The ALERT trial, conducted in collaboration with Medtronic Plc (NYSE:MDT), demonstrated that automated electronic clinician notifications significantly improve the timely evaluation and treatment of patients with significant valvular heart disease.

Specifically, the study found a 40% relative increase in life-saving valve procedures and a 27% increase in multidisciplinary heart team evaluations within just 90 days.

Tempus AI-Driven Alerts Aim To Close Care Gaps

The trial included 765 clinicians and 2,016 echocardiograms across five U.S. health systems, highlighting the potential for AI-driven alerts to bridge critical gaps in care delivery.

The findings suggest that integrating clinical decision support into EHRs can standardize care delivery, ensuring timely action regardless of a patient’s demographics.

Tempus AI Merck Collaboration Expands Precision Medicine Push

In March, Tempus AI inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE:MRK) aimed at accelerating AI-driven precision medicine.

Tempus announced an expanded, multi-year collaboration with Merck to enhance the discovery and development of precision medicine biomarkers.

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $72.00. Recent analyst moves include:

  • Guggenheim: Buy (Lowers Target to $60.00) (Mar. 30)
  • Needham: Buy (Maintains Target to $75.00) (Mar. 11)
  • HC Wainwright & Co.: Buy (Raises Target to $95.00) (Mar. 9)

TEM Stock Price Activity: Tempus AI shares were up 3.54% at $46.82 at the time of publication on Wednesday, according to Benzinga Pro data.

Image via Shutterstock